Loading…
Employees: 27
Size Anbio Biotechnology (NNNN) is a United States Health Care company (Medical Specialties) with a market value of $560M, the 2618th largest of 3,117 United States companies the cockpit tracks. Shares closed at $3.89 on 6 Nov 2026.
Performance Over six months the shares fell 85.0%, against -13.2% for the median peer and -1.1% for the United States market (cap-weighted) — lowest of 20 in its peer set.
Growth Revenue grew 10.2% over the last twelve months (peer median +5.8%); the operating margin is 66.7% (peer median 4.4%).
Short interest Short interest is 0.1% of the free float (15 Oct 2026).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | n/a | $9.76M | $8.85M | $7.26M | $24.7M |
| Revenue growth | — | +10% | +22% | -71% | — |
| Gross profit | n/a | $8.51M | $6.37M | $3.63M | $13.2M |
| EBITDA | n/a | $6.51M | $2.16M | $2.13M | $10.7M |
| Net income | n/a | $7.23M | $2.57M | $2.44M | $10.5M |
| Free cash flow | n/a | -$7.61M | $2.25M | $971,240 | $4.72M |
| Capital expenditure | n/a | $0 | $0 | $0 | $0 |
| Total debt | n/a | $0 | $0 | $0 | $0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NNNN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -15.8% | -3.3% | 2nd lowest of 20 |
| 6-month return | -85.0% | -13.2% | lowest of 20 |
| Distance from 52-week high | -91.3% | -37.3% | lowest of 20 |
| Revenue growth (TTM) | +10.2% | +5.8% | 7th highest of 20 |
| Operating margin | 66.7% | 4.4% | highest of 20 |
| Net debt / EBITDA | -2.1× | -3.5× | 4th least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Anbio Biotechnology NNNN | United States | $560M | -85% | +10% | 67% | n/a | n/a | n/a |
| Zhejiang Orient Gene Biotech 688298.SS | China | $559M | -17% | +18% | -60% | 2.0× | n/a | n/a |
| MedicalSystem Biotechnology 300439.SZ | China | $556M | -4% | +14% | 2% | 1.7× | 7.4% | -7.8% |
| Sight Sciences SGHT | United States | $555M | -14% | +9% | -33% | 6.2× | n/a | n/a |
| Anteris Technologies Global AVR | United States | $555M | -14% | -10% | -4,738% | 134.2× | n/a | n/a |
| Sahajanand Medical Technologies SMT.NS | India | $566M | n/a | n/a | n/a | n/a | n/a | n/a |
| Myriad Genetics MYGN | United States | $566M | +38% | -3% | -11% | 0.8× | n/a | n/a |
| Guangdong Hybribio Biotech 300639.SZ | China | $568M | -5% | -7% | 4% | 4.5× | 2.7% | -13.2% |
| Nanjing Vishee Medical Technology 688580.SS | China | $550M | -40% | +7% | 24% | 6.0× | 22.3% | +4.2% |
| Medprin Regenerative Medical Technologies 301033.SZ | China | $542M | -3% | +23% | 31% | 8.0× | 6.3% | +24.4% |
| Zhejiang Gongdong Medical Technology 605369.SS | China | $581M | -10% | +6% | 9% | 2.8× | 11.6% | +6.5% |
| Assure Tech (Hangzhou) 688075.SS | China | $538M | -25% | -21% | -7% | n/a | n/a | n/a |
| Tactile Systems Technology TCMD | United States | $583M | +1% | +14% | 9% | 1.5× | 7.8% | +12.0% |
| Zhejiang Starry Pharmaceutical 603520.SS | China | $537M | -32% | +9% | 3% | 2.3× | n/a | n/a |
| medmix MEDX.SW | Switzerland | $537M | +24% | -7% | 6% | 1.5× | 5.0% | +5.0% |
| Jin Medical International ZJYL | United States | $532M | +53% | -14% | 2% | 26.5× | n/a | n/a |
| Nanosonics NAN.AX | Australia | $599M | -13% | +3% | 7% | 3.6× | 34.4% | +6.7% |
| Contec Medical Systems 300869.SZ | China | $600M | -23% | -2% | -16% | 6.3× | 17.3% | -19.8% |
| Medistim MEDI.OL | Norway | $601M | +30% | +19% | 29% | 6.8× | -1.8% | +14.5% |
| Hangzhou Alltest Biotech 688606.SS | China | $521M | -15% | 0% | 13% | 1.6× | -3.9% | -4.3% |
| Wuhan Huakang Century Clean Technology 301235.SZ | China | $603M | -42% | +28% | 7% | 1.7× | n/a | n/a |